

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### The comparisone of effects of Tranexamic acid and Medroxyprogestrone on puerperal bleeding

#### Protocol summary

##### Summary

The purpose of this study is determining the effects of Tranexamic acid and Medroxyprogestrone acetate on puerperal bleeding .Inclusion criteria: Puerperal bleeding more than 30 days; dizziness; hypotension. Exclusion criteria: Birth canal lacerations; retained placenta . 66 patients who refer to Imam Reza hospital will evaluate.One group under treatment with tranexamic acid and the other group under treatment with medroxy progestrone acetate.6 weeks later they will evaluate for response to treatment; reduce bleeding; Hb level and side effects.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201306193461N6**  
Registration date: **2013-08-06, 1392/05/15**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2013-08-06, 1392/05/15

##### Registrant information

##### Name

Firoozeh Veisi

##### Name of organization / entity

Kermanshah University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 83 1823 4276

##### Email address

f\_veisi@kums.ac.ir

##### Recruitment status

##### Recruitment complete

##### Funding source

Kermanshah University of Medical Sciences,Kermanshah, Iran

##### Expected recruitment start date

2013-04-21, 1392/02/01

##### Expected recruitment end date

2015-04-21, 1394/02/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The comparisone of effects of Tranexamic acid and Medroxyprogestrone on puerperal bleeding

##### Public title

The effect of tranexamic acid and medroxyprogestrone on puerperal bleeding

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criterias: women 15-45 ages with prolonged puerperal bleeding; dizziness; hypotension; skin allergy because of tampon use;and 30 days after delivery. Exclusion critreias: Birth canal lacerations; retained placenta; myoma and endometrial polyps; history of chronic diseases such as: hepatic, renal,diabetes, thromboembolic and coagulative disorders; anticoagulative drug use ; and thrombocytopenia.

##### Age

From **15 years** old to **45 years** old

##### Gender

Female

##### Phase

N/A

##### Groups that have been masked

No information

### Sample size

Target sample size: 66

### Randomization (investigator's opinion)

Randomized

### Randomization description

### Blinding (investigator's opinion)

Double blinded

### Blinding description

### Placebo

Not used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Kermanshah University of Medical Sciences

##### Street address

Kermanshah, Daneshgah Blv, Parastar Ave.

##### City

Kermanshah

##### Postal code

#### Approval date

2013-02-12, 1391/11/24

#### Ethics committee reference number

1504

## Health conditions studied

### 1

#### Description of health condition studied

puerperal bleeding

#### ICD-10 code

090.9

#### ICD-10 code description

complications of the the puerperium unspecified

## Primary outcomes

### 1

#### Description

The volume of bleeding

#### Timepoint

Before and six weeks after intervention

#### Method of measurement

The number of used pads before and after intervention

### 2

#### Description

Hb level

### Timepoint

Before and six weeks after intervention

### Method of measurement

Hb level measurement

## Secondary outcomes

### 1

#### Description

Headache and dizziness

#### Timepoint

Before and six weeks after intervention

#### Method of measurement

Patient report

### 2

#### Description

Spotting

#### Timepoint

Before and six weeks after intervention

#### Method of measurement

Patient report

### 3

#### Description

Repeat intervention

#### Timepoint

Up to six weeks after intervention

#### Method of measurement

Surgery, D&C, administration of drug

## Intervention groups

### 1

#### Description

Group A: every 12 hour, 250 mg oral tranexamic acid capsule with two ferrous sulfate is given.

#### Category

Treatment - Drugs

### 2

#### Description

Group B: every 12 hour 1 tablet 5 mg medroxyprogesterone with two ferrous sulfate is given

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Imam Reza Hospital clinic

##### Full name of responsible person

##### Street address

##### City

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

firoozeh veisi

**Street address**

Kermanshah, Imam Reza Hospital

**City**

Kermanshah

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kermanshah University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

firoozeh veisi

**Position**

Assistant professor

**Other areas of specialty/work**

**Street address**

Kermanshah ,Imam Reza Hospital

**City**

Kermanshah

**Postal code**

**Phone**

+98 83 1427 6309

**Fax**

**Email**

f\_veisi@kums.ac.ir firoozehveisi@yahoo.com

**Web page address**

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

firoozeh veisi

**Position**

Assistant professor

**Other areas of specialty/work**

**Street address**

Kermanshah University of Medical Sciences

**City**

Kermanshah

**Postal code**

**Phone**

+98 83 1427 6309

**Fax**

**Email**

f\_veisi@kums.ac.irfiroozehveisi@yahoo.com

**Web page address**

## Person responsible for updating data

#### Contact

**Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

firoozeh veisi

**Position**

Assistant Professor

**Other areas of specialty/work**

**Street address**

Kermanshah, Imam Reza Hospital

**City**

Kermanshah

**Postal code**

**Phone**

+98 83 1427 6309

**Fax**

**Email**

f\_veisi@kums.ac.irfiroozehveisi@yahoo.com

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*